|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01875 TOT BIOPHARM-B
Nominal 
2.090 +0.140 (+7.179%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 1,098,329 | 40.698% | 780,629 | 442,178 | 76,325 | 22,491 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 8,005 | -- | (11,481) | (597) | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | (2,495) | (6,633) | (17) | 0 | |
| Profit / (Loss) before Taxation | 34,757 | -- | (37,756) | (50,046) | (261,216) | (288,498) | |
| Taxation | 0 | -- | (1) | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 130 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 34,757 | -- | (37,757) | (49,916) | (261,216) | (288,498) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 6,497 | 195.184% | 2,201 | 4,337 | 1,499 | (174) |
| Depreciation & Amortisation | -- | -- | 43,028 | 38,039 | 34,237 | 32,082 |
| Directors' Emoluments | -- | -- | 8,974 | 8,368 | 7,196 | 7,683 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 5.000 | -- | -5.000 | -8.000 | -46.000 | -51.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.078 | 0.094 | (0.305) | (0.461) |
| NBV per share ($) | 0.944 | -- | 0.889 | 0.924 | 0.545 | 0.970 |
| Remarks: | Real time quote last updated: 14/03/2025 16:06 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 34,757 |
| %Change | -- |
| EPS / (LPS) | RMB 0.050 |
| NBV Per Share (¥) | RMB 0.944 |